T CELL RECONSTITUTION AFTER STEM CELL AUTOGRAFTING
干细胞自体移植后 T 细胞重建
基本信息
- 批准号:6017567
- 负责人:
- 金额:$ 27.43万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1999
- 资助国家:美国
- 起止时间:1999-07-01 至 2004-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION: (Verbatim from Investigator's abstract):
Background: The recovery of CD4 T cells after high-dose chemo/radiotherapy in
adult patients with cancer or autoimmune diseases is very slow (years) and may
result in only limited T cell repertoire. A similar problem exists in AIDS
patients treated with highly active anti-retroviral therapy. With the ultimate
goal of designing strategies to improve the T cell regeneration after T
lymphocytopenia, here we propose to study the mechanism of the T cell
regeneration.
Hypothesis: We hypothesize that after T-lymphocytopenia a substantial number of
regenerating T cells originate from hemopoietic progenitors in young
individuals whereas only few, if any, T cells originate from hemopoietic
progenitors in older individuals. Instead, in the older individuals, the vast
majority of T cells originate from the expansion of preexisting T cells.
Methods: This hypothesis will be tested in severely lymphocytopenic patients
with autoimmune diseases who have received high-dose chemo/radiotherapy plus
anti-thymocyte globulin followed by autologous transplantation of hemopoietic
(CD34+) cells. An extremely limited number of T cell clones survive such
transplant conditioning/ CD34+ cell purification. Therefore, it is relatively
easy (easier and more informative than in patients with only moderate T
lymphocytopenia) to track down the fate of the surviving T cell clones and to
detect T cells newly generated from hemopoietic progenitors post-transplant,
using the following techniques: spectratyping, sequencing of the T cell
receptor genes within a single spectratyping band, and quantifying T cells that
contain T cell receptor-rearrangement excision circles (TREC).
Outcome: If the above hypothesis is true, the repertoire of T cells, that is
severely limited within the first several months after transplant, will later
diversify in young (less than 5-years-old) whereas it will stay severely
limited in older (greater than 45-years-old) patients. Also, if the hypothesis
is true, the number of TREC-containing T cells post-transplant will be
significantly higher in the young compared to the older patients. This will
give impetus for developing strategies to enable older patients to generate T
cells from hemopoietic progenitors, e.g., using thymopoietic cytokines or
thymus grafting.
描述:(逐字摘自研究者摘要):
背景:大剂量化疗/放疗后CD 4 T细胞的恢复,
患有癌症或自身免疫性疾病的成年患者非常缓慢(数年),
导致仅有限的T细胞库。艾滋病也存在类似的问题
接受高效抗逆转录病毒治疗的患者。其最终
目的是设计策略,以改善T细胞再生后,
淋巴细胞减少症,在这里,我们建议研究T细胞的机制,
再生
假设:我们假设T淋巴细胞减少后,
再生T细胞来源于年轻人的造血祖细胞
然而,只有很少的T细胞,如果有的话,来自造血干细胞。
老年人的祖先。相反,在年长的个体中,
大多数T细胞来源于预先存在的T细胞的扩增。
方法:将在严重淋巴细胞减少症患者中检验这一假设
患有自身免疫性疾病的患者接受了大剂量化疗/放疗,
抗胸腺细胞球蛋白后自体移植造血细胞
(CD34+)细胞。只有极少数的T细胞克隆能够存活下来,
移植预处理/CD 34+细胞纯化。因此,相对而言,
容易(比只有中度T的患者更容易,信息量更大)
淋巴细胞减少症)追踪存活的T细胞克隆的命运,
检测移植后从造血祖细胞新产生的T细胞,
使用以下技术:光谱分析、T细胞测序
受体基因在单个谱带内,并定量T细胞,
含有T细胞受体重排切除环(TREC)。
结果:如果上述假设是正确的,T细胞的库,即
移植后的头几个月内严重受限,
在年轻时(不到5岁)多样化,而它将保持严重
仅限于老年(大于45岁)患者。此外,如果假设
是真的,移植后含有TREC的T细胞的数量将是
年轻患者的死亡率明显高于老年患者。这将
推动制定战略,使老年患者能够产生T
来自造血祖细胞的细胞,例如,使用胸腺生成细胞因子或
胸腺移植
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JAN STOREK其他文献
JAN STOREK的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JAN STOREK', 18)}}的其他基金
Preclinical Testing of Interleukin-7 in Primates
Interleukin-7 在灵长类动物中的临床前测试
- 批准号:
6319291 - 财政年份:2001
- 资助金额:
$ 27.43万 - 项目类别:
Preclinical Testing of Interleukin-7 in Primates
Interleukin-7 在灵长类动物中的临床前测试
- 批准号:
6528196 - 财政年份:2001
- 资助金额:
$ 27.43万 - 项目类别:
Preclinical Testing of Interleukin-7 in Primates
Interleukin-7 在灵长类动物中的临床前测试
- 批准号:
6644818 - 财政年份:2001
- 资助金额:
$ 27.43万 - 项目类别:
T CELL RECONSTITUTION AFTER STEM CELL AUTOGRAFTING
干细胞自体移植后 T 细胞重建
- 批准号:
6374275 - 财政年份:1999
- 资助金额:
$ 27.43万 - 项目类别:
T CELL RECONSTITUTION AFTER STEM CELL AUTOGRAFTING
干细胞自体移植后 T 细胞重建
- 批准号:
6510906 - 财政年份:1999
- 资助金额:
$ 27.43万 - 项目类别:
T CELL RECONSTITUTION AFTER STEM CELL AUTOGRAFTING
干细胞自体移植后 T 细胞重建
- 批准号:
6170806 - 财政年份:1999
- 资助金额:
$ 27.43万 - 项目类别:
T CELL RECONSTITUTION AFTER STEM CELL AUTOGRAFTING
干细胞自体移植后 T 细胞重建
- 批准号:
6613452 - 财政年份:1999
- 资助金额:
$ 27.43万 - 项目类别:
B CELL TRANSFUSIONS FOR POSTBMT IMMUNE DEFICIENCY
B 细胞输注治疗 TBMT 后免疫缺陷
- 批准号:
2112477 - 财政年份:1995
- 资助金额:
$ 27.43万 - 项目类别:
B CELL TRANSFUSIONS FOR POSTBMT IMMUNE DEFICIENCY
B 细胞输注治疗 TBMT 后免疫缺陷
- 批准号:
2895387 - 财政年份:1995
- 资助金额:
$ 27.43万 - 项目类别:
相似海外基金
MOUSE MONOCLONAL ANTIBODIES AGAINST HUMAN CD4 MOLECULE GENERATE MONOCLONAL ANT
抗人 CD4 分子的小鼠单克隆抗体生成单克隆蚂蚁
- 批准号:
3810218 - 财政年份:
- 资助金额:
$ 27.43万 - 项目类别:
MOUSE MONOCLONAL ANTIBODIES AGAINST HUMAN CD4 MOLECULE
针对人 CD4 分子的小鼠单克隆抗体
- 批准号:
3803662 - 财政年份:
- 资助金额:
$ 27.43万 - 项目类别:
MOUSE MONOCLONAL ANTIBODIES AGAINST HUMAN CD4 MOLECULE GENERATE MONOCLONAL ANT
抗人 CD4 分子的小鼠单克隆抗体生成单克隆蚂蚁
- 批准号:
3814788 - 财政年份:
- 资助金额:
$ 27.43万 - 项目类别:
MOUSE MONOCLONAL ANTIBODIES AGAINST HUMAN CD4 MOLECULE GENERATE MONOCLONAL ANT
抗人 CD4 分子的小鼠单克隆抗体生成单克隆蚂蚁
- 批准号:
3818867 - 财政年份:
- 资助金额:
$ 27.43万 - 项目类别: